---
title: "GLP-1 Receptor Agonists in Rheumatic Disease: Mechanisms, Evidence, and Clinical Considerations"
id: "pubmed-42706128"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42706128"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42706128/"
doi: "10.3760/cma.j.cn112137-20260312-00692"
published_at: "2026-09-08T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 Receptor Agonists in Rheumatic Disease: Mechanisms, Evidence, and Clinical Considerations
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42706128
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42706128/)
- **DOI:** [10.3760/cma.j.cn112137-20260312-00692](https://doi.org/10.3760%2Fcma.j.cn112137-20260312-00692)
- **Published At:** 2026-09-08T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Glucagon-like peptide-1 receptor agonists (**GLP-1RA**) were developed for type 2 diabetes and obesity but have received growing attention in rheumatology for their **pleiotropic** metabolic, anti-inflammatory, and tissue-protective effects. - GLP-1RA reduce inflammation both indirectly by inducing **weight loss** and improving metabolic status, and directly via actions on GLP-1 receptors expressed on immune cells and musculoskeletal cells, producing anti-inflammatory and protective effects independent of weight change. - Clinical signals from several large real-world cohorts and randomized controlled trials suggest potential benefit of GLP-1RA in osteoarthritis, rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, and systemic lupus erythematosus (SLE), including improvements in disease activity metrics and reductions in cardiovascular events and mortality. - Available evidence has important limitations: many studies are retrospective, sample sizes are often limited, different GLP-1RA agents are commonly grouped together, and it is difficult to separate benefits attributable to weight loss from direct immunomodulatory effects. - Randomized controlled trials in non-obese, non-diabetic rheumatic populations are lacking, leaving an evidence gap about efficacy independent of metabolic comorbidity. - The authors recommend currently restricting GLP-1RA use in rheumatic patients to those with overweight/obesity or type 2 diabetes who also have high cardiovascular risk. - Priority areas for future research include head-to-head comparisons among different GLP-1RA agents, mechanistic studies designed to dissociate weight-loss effects from direct actions, and exploration of combination treatment strategies in rheumatic disease. - The review emphasizes cautious optimism: GLP-1RA may herald a new “metabolic-immune” synergistic approach in rheumatology, but benefits and risks require careful evaluation. - Conflict of interest: the authors declared no conflicts. Funding sources listed include National Natural Science Foundation of China grants 82302018 and 82372369.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42706128/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706128%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42706128/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42706128/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42706128/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42706128/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42706128/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706128%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706128%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42706128/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42706128/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42706128/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42706128/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42706128/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42706128/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42706128/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42706128/#conflict-of-interest) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42706128/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42706128/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42706128/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42706128/#grants) Title & authors Abstract Conflict of interest statement Publication types MeSH terms Substances Grants and funding Review Zhonghua Yi Xue Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) . 2026 Sep 8;106(33):3431-3437. doi: 10.3760/cma.j.cn112137-20260312-00692. # [Glucagon-like peptide-1 receptor agonists: from metabolic regulation to rheumatic disease therapy] [Article in Chinese] [W H Xie](https://pubmed.ncbi.nlm.nih.gov/?term=Xie+WH&cauthor_id=42706128)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706128/#full-view-affiliation-1 "Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China."), [T Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+T&cauthor_id=42706128)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706128/#full-view-affiliation-1 "Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China."), [Z L Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+ZL&cauthor_id=42706128)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706128/#full-view-affiliation-1 "Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China.") Affiliations Expand ### Affiliation * 1 Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China. * PMID: **42706128** * DOI: [ 10.3760/cma.j.cn112137-20260312-00692 ](https://doi.org/10.3760/cma.j.cn112137-20260312-00692) Item in Clipboard Review # [Glucagon-like peptide-1 receptor agonists: from metabolic regulation to rheumatic disease therapy] [Article in Chinese] W H Xie et al. Zhonghua Yi Xue Za Zhi. 2026. Show details Display options Display options Format Abstract PubMed PMID Zhonghua Yi Xue Za Zhi Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Zhonghua+Yi+Xue+Za+Zhi%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) . 2026 Sep 8;106(33):3431-3437. doi: 10.3760/cma.j.cn112137-20260312-00692. ### Authors [W H Xie](https://pubmed.ncbi.nlm.nih.gov/?term=Xie+WH&cauthor_id=42706128)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706128/#short-view-affiliation-1 "Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China."), [T Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+T&cauthor_id=42706128)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706128/#short-view-affiliation-1 "Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China."), [Z L Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+ZL&cauthor_id=42706128)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42706128/#short-view-affiliation-1 "Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China.") ### Affiliation * 1 Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China. * PMID: **42706128** * DOI: [ 10.3760/cma.j.cn112137-20260312-00692 ](https://doi.org/10.3760/cma.j.cn112137-20260312-00692) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract in [ English, ](https://pubmed.ncbi.nlm.nih.gov/42706128/#eng-abstract) [ Chinese ](https://pubmed.ncbi.nlm.nih.gov/42706128/#zho-abstract) Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), originally developed for type 2 diabetes mellitus and obesity, have attracted considerable attention in rheumatology due to their pleiotropic effects. Accumulating evidence indicates that GLP-1RA not only indirectly reduce inflammation through weight loss and metabolic improvement, but also directly act on GLP-1 receptors expressed on immune cells and musculoskeletal cells, exerting anti-inflammatory and tissue-protective effects independent of weight reduction. In recent years, several large real-world studies and randomized controlled trials have shown that GLP-1RA may improve disease activity and reduce cardiovascular events and mortality in osteoarthritis, rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, and systemic lupus erythematosus (SLE). However, the available evidence has notable limitations: most studies are retrospective, with limited sample sizes; different GLP-1RA are often analyzed as a single class; the weight-loss effect is difficult to dissociate from direct anti-inflammatory action; and randomized controlled trials in non-obese, non-diabetic rheumatic patients are lacking. This review systematically summarizes the molecular mechanisms and clinical evidence of GLP-1RA in rheumatic diseases (including RA, psoriasis/psoriatic arthritis, osteoarthritis, and SLE), and based on this, the authors' perspective is put forward: currently, GLP-1RA should only be recommended for rheumatic patients with overweight/obesity or type 2 diabetes who also have high cardiovascular risk. Future research should prioritize head-to-head comparisons of different GLP-1RA, mechanistic studies independent of weight loss, and exploration of combination strategies. It is believed that GLP-1RA hold promise to usher in a new era of "metabolic-immune" synergistic intervention in rheumatology, but their benefits and risks must be carefully evaluated. 胰高糖素样肽-1（GLP-1）受体激动剂（GLP-1RA）最初被用于治疗2型糖尿病和肥胖症，现因其多效性在风湿病领域备受关注。大量研究表明，GLP-1RA不仅通过减重和改善代谢状态间接降低炎症，更能直接作用于免疫细胞及肌肉骨骼系统细胞表面的GLP-1受体，发挥独立于减重效应的抗炎与组织保护作用。近年来，多项大型真实世界研究和随机对照试验显示GLP-1RA在骨关节炎、类风湿关节炎（RA）、银屑病/银屑病关节炎、系统性红斑狼疮（SLE）中具有改善疾病活动度、降低心血管事件发生率及死亡率的潜力。然而，现有证据仍存在显著局限性：多数研究为回顾性设计；样本量有限；不同药物混为一谈；减重效应与直接抗炎作用难以剥离；缺乏针对非代谢紊乱风湿病人群的随机对照试验等。该文系统梳理了GLP-1RA在风湿病中的分子机制，总结其应用于RA、银屑病/银屑病关节炎、骨关节炎及SLE中临床证据，并在此基础上提出作者观点：目前GLP-1RA仅应推荐用于合并超重及肥胖或2型糖尿病且伴高心血管风险的风湿病患者；未来亟需头对头比较不同药物、开展独立于减重效应的机制验证研究，以及探索联合治疗策略。总的来说，GLP-1RA有望开启风湿病“代谢-免疫”协同干预的新时代，但必须审慎评估其获益与风险。. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement 所有作者声明不存在利益冲突 ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * English Abstract Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22English+Abstract%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=English+Abstract) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) ## MeSH terms * Diabetes Mellitus, Type 2 / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fdrug+therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * Glucagon-Like Peptide-1 Receptor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * Glucagon-Like Peptide-1 Receptor Agonists* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor+Agonists) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * Rheumatic Diseases* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Rheumatic+Diseases%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Rheumatic+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) ## Substances * Glucagon-Like Peptide-1 Receptor Agonists Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) * Glucagon-Like Peptide-1 Receptor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Glucagon-Like+Peptide-1+Receptor%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42706128/) ## Grants and funding * [ 82302018, 82372369/National Natural Science Foundation of China ](https://pubmed.ncbi.nlm.nih.gov/?term=82302018%2C+82372369%2FNational+Natural+Science+Foundation+of+China%5BGrants+and+Funding%5D&sort=date&sort_order=desc "All articles for grant 82302018, 82372369/National Natural Science Foundation of China") [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42706128/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706128%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42706128/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706128%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42706128%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42706128/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/)
## Related Clinical Research

- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [Natural GLP-1 discovery hidden in joints could revolutionize arthritis treatment](https://medichelpline.com/clinical-feed/medical-news-today-0-natural-glp-1-discovery-hidden-in-joints-could-revolutionize-arthritis-treatment.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [GLP-1 Receptor Agonists Linked to Fewer 90-Day Complications After Total Hip and Knee Arthroplasty](https://medichelpline.com/clinical-feed/pubmed-42538001.md) (DOI: 10.1302/0301-620X.108B8.BJJ-2025-1486.R2)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.